Title |
Genome editing for inborn errors of metabolism: advancing towards the clinic
|
---|---|
Published in |
BMC Medicine, February 2017
|
DOI | 10.1186/s12916-017-0798-4 |
Pubmed ID | |
Authors |
Jessica L. Schneller, Ciaran M. Lee, Gang Bao, Charles P. Venditti |
Abstract |
Inborn errors of metabolism (IEM) include many disorders for which current treatments aim to ameliorate disease manifestations, but are not curative. Advances in the field of genome editing have recently resulted in the in vivo correction of murine models of IEM. Site-specific endonucleases, such as zinc-finger nucleases and the CRISPR/Cas9 system, in combination with delivery vectors engineered to target disease tissue, have enabled correction of mutations in disease models of hemophilia B, hereditary tyrosinemia type I, ornithine transcarbamylase deficiency, and lysosomal storage disorders. These in vivo gene correction studies, as well as an overview of genome editing and future directions for the field, are reviewed and discussed herein. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 13% |
Unknown | 7 | 88% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 8 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 103 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 20 | 19% |
Student > Bachelor | 20 | 19% |
Student > Master | 18 | 17% |
Student > Ph. D. Student | 13 | 13% |
Student > Doctoral Student | 4 | 4% |
Other | 14 | 14% |
Unknown | 14 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 43 | 42% |
Agricultural and Biological Sciences | 13 | 13% |
Medicine and Dentistry | 12 | 12% |
Engineering | 5 | 5% |
Nursing and Health Professions | 3 | 3% |
Other | 13 | 13% |
Unknown | 14 | 14% |